

Group 2 – All below should focus on a **solution-based perspective**

- **Preparedness** for new pandemic or epidemic crises or increase in all types of AMR, esp. in LMICs; politics that could enable or be a barrier.
 - Would include OH **Equity issues**
 - Timely
 - 2019 Berlin OH Principles – what are the metrics to monitor OH principles? (not nec. quantitative)
 - Country comparison for OH implementation with PVS, IHR, ATLAS (for AMR)
 - How better prioritise surveillance for emergence of AMR? Decision tools or methods. Human-animal-environment
 - CIPARS – CIFAR – program on fungal agents (Agnes?)
 - OH should be able to look at commonalities across infectious agents and resistance
 - Include the industry (for ex. CIRAD in France)
- **Knowledge synthesis** of what is being done with a multi-disciplinary group
 - How can we do this? General lessons learned
 - Case study with action items
 - Audience? Decision makers at all levels (i.e. industry, community-level, higher levels)